Compare Bristol-Myers Squibb Co (BMY) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Virgin Galactic Holdings, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $58.45 (market cap $116.30B), while Virgin Galactic Holdings, Inc. trades at $2.69 (market cap $335.48M). The key difference: Bristol-Myers Squibb Co is far larger — about 346.7× Virgin Galactic Holdings, Inc.'s market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| BMY | SPCE | |
|---|---|---|
Market Cap | $116.30B | $335.48M |
Sector | Health | Industrials |
52-Week High | $62.37 | $7.52 |
52-Week Low | $42.60 | $2.17 |
Enterprise Value | $152.24B | $435.33M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
SPCE trades at $2.42, down 5.84% over 24 hours, reflecting ongoing volatility amid negative profitability. The company reported a net loss of $278.91 million on minimal revenue of $1.54 million in 2025, with cash burn persisting despite narrowing losses. Technical indicators are mixed, with a bearish moving average signal but oversold RSI levels, while analyst consensus is divided with a slight hold bias.
The outlook remains speculative, with opportunities tied to future commercial spaceflight execution, but risks are elevated due to persistent losses, high cash burn, and significant debt. Investor sentiment is cautious, driven by the unproven business model and competitive pressures in the space sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
